

☐ Non-Invasive Prenatal Test - NIPT
☐ Non-Invasive Prenatal Test - NIPT Microdeletion

(To be filled in by patient)

Vial ID:

Patient	Name	SIKHA MEDHI		Date of Birth	DD/MM/YYYY 10-3-92	ID/Passport No	
	Address	Mirza Kamrup Assom				Contact number	8486978285
	Weight	56 kg	Blood Type		Inherited Disease ☒ NO ☐ YES		
Pregnancy	Gestation Period <u>14</u> Weeks			Pregnancy type ☒ Singleton ☐ Multiple			
	Past history of Gestation Abnormality ☒ No ☐ Yes						

(To be filled in by Clinical/Medical Institution)

Pregnancy profile	Doctor	Undergoing IVF ☐ No ☐ Yes (Number of embryos: Implantation _____ Blighted ovum _____ Fetal reduction _____)					
	Down Syndrome test	☐ none so far ☐ NT _____ Notes: _____ T21 _____ T18 _____ T13 _____					
Sample info	Medical Institution	Contact number	Blood taken by	Blood quantity	mL		
	Blood collection date		Blood pick up date				
Collection agent		Condition of blood	Blood ID				

Purpose and method of the test

The Firstvue NIPT (Non Invasive Prenatal Testing) was developed by PathCare Labs. This test is designed to screen for Trisomy 13 (Patau syndrome), Trisomy 18 (Edwards syndrome) and Trisomy 21 (Down syndrome). The test is performed by first collecting a 10 ml blood sample from an expectant mother at least 10 weeks into the pregnancy. Cell-free fetal DNA is then extracted from the blood sample for subsequent DNA sequencing. Through innovative next-generation DNA sequencing technology, and specialized bioinformatics analysis, this test platform has a detection rate of over 99.9% for the above-mentioned genetic anomalies.

Recommended use of this test:

The Firstvue NIPT should be considered after close consultation with your physician and if possible a genetic counselor.

The test is recommended in cases where:

1. Patients are concerned about the risk of invasive prenatal diagnosis, and/or
2. Patients have unusual ultrasonography findings which suggest chromosome abnormality, and/or
3. Patients are of advanced maternal age and/or have a higher risk of their fetus being diagnosed with Down syndrome.

Test Results:

The test report will indicate a Positive (aneuploidy detected) or Negative (aneuploidy not detected) result for each of the conditions listed above.

In very few cases, the test does not report any results. In these circumstances, PathCare Labs will provide a free re-test. If the re-test produces no results, the patient will be refunded the initial cost of the test.

Important considerations:

This test does not reveal the gender of the fetus.

If one or both of the parents have a balanced Robertsonian Translocation involving chromosome 21, please consult your physician about the applicability of this test.

Although the detection rate of this test is very high, like all other non-invasive prenatal tests (NIPTs) based on the analysis of cell-free fetal DNA, this test is currently classified as a screening test. A diagnostic test such as Amniocentesis or Chorionic Villus Sampling (CVS) is typically recommended for tests that return positive results. Therefore, the results of

this NIPT serve as a reference for your physician to suggest further treatment.

The accuracy and quality of the test may be adversely affected by improper blood sample collection, storage and transportation. The accuracy and quality of the test may also be adversely affected by samples taken from patients that have received medical treatment including allogeneic blood transfusion, transplant operations, and stem cell therapy within 30 days of sample collection.

This test is not suitable for:

- Patients with dry spots/multiple gestation
- Patients with diagnostic results that have revealed chromosomal aneuploidy
- Patients who have previously accepted blood transfusion from other than themselves, or have undergone transplantation surgery, stem cell therapy or organ donation
- Patients of less than 10 weeks gestation
- Patients who have tested positive for HIV and/or Hepatitis B/C

Limitations of the test:

Chromosomal abnormalities such as chromosomal rearrangements, duplications, copy number variations, balanced translocations, inversions, unbalanced translocations, uniparental disomy, monosomy etc., are not within the scope of detection. Therefore, this test does not guarantee that a fetus will be free from a genetic disease. NIPT Microdeletion test is a risk assessment test only and does not guarantee that a fetus will be free from genetic microdeletion.

Informed consent:

If the NIPT test result is high risk, PathCare will reimburse the cost of further confirmatory diagnostic tests including amniocentesis, CVS and chromosome fluorescence in situ hybridization (FISH).

Privacy and confidentiality:

PathCare Labs respects the privacy and confidentiality of your personal information. The information

collected on this form (including any relevant medical history) is collected only for the sole purpose of conducting the test

and will not be used in any manner to the contrary.

If you have any questions or would like further clarification, please call the local PathCare Labs representative or the relevant partner laboratory.

Patient Signature

Sikha Medhi

Doctor's Signature

Patient E-mail

Doctor's E-mail: